- Report
- September 2025
- 284 Pages
Global
From €5164EUR$5,850USD£4,467GBP
- Report
- April 2025
- 200 Pages
Global
From €2198EUR$2,490USD£1,901GBP
- Report
- August 2025
- 184 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 191 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 189 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 191 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 193 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 192 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 180 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 189 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 192 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 196 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 194 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 191 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 190 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 189 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 187 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 186 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 186 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 193 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP

The Neuroprotective market is a subset of Central Nervous System (CNS) drugs that are designed to protect the brain and spinal cord from damage caused by disease, trauma, or other conditions. Neuroprotective drugs are used to treat a variety of neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. These drugs can also be used to reduce the risk of developing these conditions. Neuroprotective drugs work by reducing inflammation, improving blood flow, and protecting neurons from damage.
Neuroprotective drugs are an important part of treating neurological disorders, as they can help reduce the severity of symptoms and improve quality of life. They are also used to prevent further damage to the brain and spinal cord.
Some companies in the Neuroprotective market include AbbVie, AstraZeneca, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more